Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470036678> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2470036678 endingPage "61" @default.
- W2470036678 startingPage "1856" @default.
- W2470036678 abstract "To evaluate the associations of soluble serum interleukin-2 receptor (sIL-2R) levels in patients with rheumatoid arthritis (RA) with clinical and laboratory measures of disease activity and the predicted response to therapy.sIL-2R levels were determined by ELISA in 137 patients with RA, not previously treated with 2nd line therapy. Patients were enrolled in a prospective, randomized, placebo controlled trial of sulfasalazine (SSZ) versus gold sodium thiomalate (GSTM), sponsored by the Cooperative Systematic Studies of Rheumatic Diseases. Using correlation analysis and regression modeling, the clinical utility of sIL-2R as a measure of disease activity and predictor of outcome was assessed.91 women and 46 men with a mean age of 51 +/- 13 years and mean duration of disease of 64 +/- 78 months participated in this study. The mean sIL-2R level in all patients with RA was markedly elevated (980 +/- 589 U/ml) compared with that in healthy control subjects (446 +/- 196 U/ml; p = < 0.0001). There was no correlation between the sIL-2R levels and the joint pain/tenderness count, either at study entry or completion. There were significant positive correlations between the baseline sIL-2R and baseline erythrocyte sedimentation rate (ESR) and between the change in sIL-2R and the change in ESR. Both a multiple linear regression model and a multiple logistic regression model showed that baseline sIL-2R levels were not predictive of clinical outcome.sIL-2R levels are significantly elevated in patients with active RA and correlate positively with ESR. However, these results indicate that in patients with early RA, sIL-2R levels are neither associated with standard disease activity criteria nor predictive of the response to therapy with SSZ or GSTM, even after controlling for the simultaneous effects of other important clinical variables." @default.
- W2470036678 created "2016-07-22" @default.
- W2470036678 creator A5020984128 @default.
- W2470036678 creator A5043781378 @default.
- W2470036678 creator A5048496421 @default.
- W2470036678 creator A5051994664 @default.
- W2470036678 creator A5088397261 @default.
- W2470036678 date "1996-11-01" @default.
- W2470036678 modified "2023-09-23" @default.
- W2470036678 title "Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo." @default.
- W2470036678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8923356" @default.
- W2470036678 hasPublicationYear "1996" @default.
- W2470036678 type Work @default.
- W2470036678 sameAs 2470036678 @default.
- W2470036678 citedByCount "3" @default.
- W2470036678 crossrefType "journal-article" @default.
- W2470036678 hasAuthorship W2470036678A5020984128 @default.
- W2470036678 hasAuthorship W2470036678A5043781378 @default.
- W2470036678 hasAuthorship W2470036678A5048496421 @default.
- W2470036678 hasAuthorship W2470036678A5051994664 @default.
- W2470036678 hasAuthorship W2470036678A5088397261 @default.
- W2470036678 hasConcept C126322002 @default.
- W2470036678 hasConcept C142724271 @default.
- W2470036678 hasConcept C204787440 @default.
- W2470036678 hasConcept C27081682 @default.
- W2470036678 hasConcept C2776232647 @default.
- W2470036678 hasConcept C2777077863 @default.
- W2470036678 hasConcept C2777575956 @default.
- W2470036678 hasConcept C2778143017 @default.
- W2470036678 hasConcept C2779134260 @default.
- W2470036678 hasConcept C2779383735 @default.
- W2470036678 hasConcept C2780479503 @default.
- W2470036678 hasConcept C2780648854 @default.
- W2470036678 hasConcept C71924100 @default.
- W2470036678 hasConcept C90924648 @default.
- W2470036678 hasConceptScore W2470036678C126322002 @default.
- W2470036678 hasConceptScore W2470036678C142724271 @default.
- W2470036678 hasConceptScore W2470036678C204787440 @default.
- W2470036678 hasConceptScore W2470036678C27081682 @default.
- W2470036678 hasConceptScore W2470036678C2776232647 @default.
- W2470036678 hasConceptScore W2470036678C2777077863 @default.
- W2470036678 hasConceptScore W2470036678C2777575956 @default.
- W2470036678 hasConceptScore W2470036678C2778143017 @default.
- W2470036678 hasConceptScore W2470036678C2779134260 @default.
- W2470036678 hasConceptScore W2470036678C2779383735 @default.
- W2470036678 hasConceptScore W2470036678C2780479503 @default.
- W2470036678 hasConceptScore W2470036678C2780648854 @default.
- W2470036678 hasConceptScore W2470036678C71924100 @default.
- W2470036678 hasConceptScore W2470036678C90924648 @default.
- W2470036678 hasIssue "11" @default.
- W2470036678 hasLocation W24700366781 @default.
- W2470036678 hasOpenAccess W2470036678 @default.
- W2470036678 hasPrimaryLocation W24700366781 @default.
- W2470036678 hasRelatedWork W190339988 @default.
- W2470036678 hasRelatedWork W1989696275 @default.
- W2470036678 hasRelatedWork W1993880151 @default.
- W2470036678 hasRelatedWork W2035596427 @default.
- W2470036678 hasRelatedWork W2221029685 @default.
- W2470036678 hasRelatedWork W2354740737 @default.
- W2470036678 hasRelatedWork W2379621749 @default.
- W2470036678 hasRelatedWork W2418176634 @default.
- W2470036678 hasRelatedWork W2910403719 @default.
- W2470036678 hasRelatedWork W2470990190 @default.
- W2470036678 hasVolume "23" @default.
- W2470036678 isParatext "false" @default.
- W2470036678 isRetracted "false" @default.
- W2470036678 magId "2470036678" @default.
- W2470036678 workType "article" @default.